Peer-influenced content. Sources you trust. No registration required. This is HCN.

JCO Precision OncologyClinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients with Non–V600 BRAF-Mutant Tumors

As yet, there are no consensus treatment strategies for class 2 and 3 BRAF mutations. This systematic review and meta-analysis of published reports of patients with class 2 or 3 BRAF mutations from 2010 to 2021 assesses MAPK targeted therapy in the setting. The meta-analysis suggests that MAPK TTs have clinical activity in some class 2 and 3 BRAF-mutant cancers.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form